Cadrenal Therapeutics, Inc. CVKD 深 滬
等待開盤 10-01 09:30:00 美东时间
13.83
+0.410
+3.06%
華盛通- 最 高13.85
- 今 開13.45
- 成交量 3.11万股
- 最 低 13.24
- 昨 收 13.42
- 總市值 2830.86万
- 52周最高 22.9011
- 市盈率 靜 --
- 換手率 1.52%
- 52周最低 8.74
- 委 比 -73.42%
- 總股本 204.69万
- 歷史最高 101.25
- 量 比 0.78
- 振 幅 4.55%
- 歷史最低 5.40
- 每 手 1
- 風險率 2.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Cadrenal Therapeutics will participate in the Lytham Partners Fall 2025 Investor Conference with a webcast at 3:30 p.m. ET on Sept. 30 and one-on-one meetings. The company, focused on overcoming gaps in anticoagulation therapy, highlights tecarfarin, an oral Vitamin K antagonist designed to address unmet needs, particularly where DOACs are inadequate. Tecarfarin has received Orphan Drug Designation for preventing blood clots in specific patient g...
09-29 20:30
Cadrenal Therapeutics Acquires eXIthera’s Assets for Growth
The latest announcement is out from Cadrenal Therapeutics, Inc. ( ($CVKD) ). On...
09-15 22:19
Cadrenal Acquires Assets Of eXIthera Pharma In $15M Milestone-Linked Deal, Adds Royalty Pathway For Future Global Sales
Acquisition significantly enhances the Company's pipeline by adding novel assets in acute and chronic anticoagulation settingsCompany is strategically poised to deliver differentiated therapeutics across the spectrum of
09-15 20:04
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
Cadrenal Therapeutics acquired eXIthera Pharmaceuticals' assets, including frunexian (Phase 2 IV Factor XIa inhibitor for acute care) and EP-7327 (IND-ready oral Factor XIa inhibitor for chronic conditions), enhancing its pipeline in the $38 billion anticoagulation market. These assets address gaps in current antithrombotic treatments, offering selective inhibitors with high potency and tunable pharmacokinetics. Cadrenal is now the only company d...
09-15 12:00
Cadrenal Therapeutics GAAP EPS of -$1.87
Cadrenal Therapeutics press release (NASDAQ:CVKD): Q2 GAAP EPS of -$1.87. On June 30, 2025, Cadrenal had cash and cash equivalents of $5.6 million, compared to $10.0 million as of December 31, 2024. T...
08-12 02:08
Cadrenal Therapeutics Q2 EPS $(1.87) Misses $(1.60) Estimate
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.87) per share which missed the analyst consensus estimate of $(1.60) by 17.09 percent. This is a 16.89 percent increase over losses of $(2.25) per
08-11 20:12
Cadrenal Therapeutics shares are trading higher after the company announced clinical trial initiation plans for its lead late-stage drug candidate, tecarfarin, in patients with ESKD who are transitioning to dialysis.
Cadrenal Therapeutics shares are trading higher after the company announced cli...
08-05 23:09
Cadrenal Therapeutics Director Resignation Announced
Cadrenal Therapeutics, Inc. ( ($CVKD) ) just unveiled an announcement. On July ...
07-19 05:19
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
Cadrenal Therapeutics Highlights Tecarfarin As Safer Anticoagulant Alternative For High-Risk LVAD Patients
LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as strokeHospitalization costs for patients following a major bleeding
06-12 20:18
